×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
Yahoo Finance
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company...
3 days ago
AGC partners with Medigene - BioProcess Insider
BioProcess International
CDMO AGC Biologics, has agreed to support Medigene with their IND filing and clinical trials to treat cancer.
2 months ago
AGC Biologics Inks TCR-T Cell Services Agreement with Medigene
Contract Pharma
AGC Biologics Inks TCR-T Cell Services Agreement with Medigene. AGC will provide autologous production for a next-generation-therapy product...
6 months ago
Shareholders in Medigene (ETR:MDG1) are in the red if they invested five years ago
Yahoo News New Zealand
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Medigene AG (ETR:MDG1) for...
2 days ago
Medigene Full Year 2023 Earnings: Beats Expectations
Simply Wall St
Medigene ( ETR:MDG1 ) Full Year 2023 Results Key Financial Results Revenue: €6.03m (down 81% from FY 2022). Net loss...
1 month ago
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene's New Cell Therapy Product
Business Wire
AGC Biologics is providing autologous clinical production for Medgine's therapy product focused on the treatment of solid cancers.
6 months ago
Medigene AG expands patent portfolio in Japan for iM-TCR Technology
BioSpectrum Asia
“The ability to control the level of TCR activity with our iM-TCR technology after dosing has the potential to deliver more individualized...
2 months ago
Cell therapy weekly: Positive Phase I/II data of HIV gene therapy
RegMedNet
This week: AGC Biologics (WA, USA) signed a service agreement to support the production of Medigene's (Planegg, Germany) TCR-T cell therapy...
6 months ago
Medigene expands pipeline into neoantigens with programs targeting KRAS mutations and HLAs
BioWorld MedTech
Medigene AG has announced its pipeline expansion into neoantigens with KRAS as the first target in its MDG-10xx program, a T-cell receptor...
11 months ago
BioNTech jumps into PRAME game, paying Medigene $29M for preclinical T-cell therapy program
Fierce Biotech
BioNTech jumps into PRAME game, paying Medigene $29M for preclinical T-cell therapy program ... BioNTech, flush with COVID-19 cash, has struck...
26 months ago